279 related articles for article (PubMed ID: 34884583)
1. CRISPR Screen Contributes to Novel Target Discovery in Prostate Cancer.
Tsujino T; Komura K; Inamoto T; Azuma H
Int J Mol Sci; 2021 Nov; 22(23):. PubMed ID: 34884583
[TBL] [Abstract][Full Text] [Related]
2. The role of the CRISPR-Cas system in cancer drug development: Mechanisms of action and therapy.
Chandrasekaran AP; Karapurkar JK; Chung HY; Ramakrishna S
Biotechnol J; 2022 Jul; 17(7):e2100468. PubMed ID: 35157790
[TBL] [Abstract][Full Text] [Related]
3. CRISPR-cas9: a powerful tool towards precision medicine in cancer treatment.
Xing H; Meng LH
Acta Pharmacol Sin; 2020 May; 41(5):583-587. PubMed ID: 31792341
[TBL] [Abstract][Full Text] [Related]
4. The Effect of Gene Editing by CRISPR-Cas9 of miR-21 and the Indirect Target MMP9 in Metastatic Prostate Cancer.
Camargo JA; Viana NI; Pimenta R; Guimarães VR; Dos Santos GA; Candido P; Ghazarian V; Romão P; Silva IA; Birbrair A; Srougi M; Nahas WC; Leite KR; Trarbach EB; Reis ST
Int J Mol Sci; 2023 Oct; 24(19):. PubMed ID: 37834295
[TBL] [Abstract][Full Text] [Related]
5. CRISPR screen in mechanism and target discovery for cancer immunotherapy.
Liu D; Zhao X; Tang A; Xu X; Liu S; Zha L; Ma W; Zheng J; Shi M
Biochim Biophys Acta Rev Cancer; 2020 Aug; 1874(1):188378. PubMed ID: 32413572
[TBL] [Abstract][Full Text] [Related]
6. CRISPR-Cas9 genome and long non-coding RNAs as a novel diagnostic index for prostate cancer therapy via liposomal-coated compounds.
Kadry MO; Abdel-Megeed RM
PLoS One; 2024; 19(5):e0302264. PubMed ID: 38723038
[TBL] [Abstract][Full Text] [Related]
7. SCNrank: spectral clustering for network-based ranking to reveal potential drug targets and its application in pancreatic ductal adenocarcinoma.
Liu E; Zhang ZZ; Cheng X; Liu X; Cheng L
BMC Med Genomics; 2020 Apr; 13(Suppl 5):50. PubMed ID: 32241274
[TBL] [Abstract][Full Text] [Related]
8. New tools for old drugs: Functional genetic screens to optimize current chemotherapy.
Gerhards NM; Rottenberg S
Drug Resist Updat; 2018 Jan; 36():30-46. PubMed ID: 29499836
[TBL] [Abstract][Full Text] [Related]
9. Agreement between two large pan-cancer CRISPR-Cas9 gene dependency data sets.
Dempster JM; Pacini C; Pantel S; Behan FM; Green T; Krill-Burger J; Beaver CM; Younger ST; Zhivich V; Najgebauer H; Allen F; Gonçalves E; Shepherd R; Doench JG; Yusa K; Vazquez F; Parts L; Boehm JS; Golub TR; Hahn WC; Root DE; Garnett MJ; Tsherniak A; Iorio F
Nat Commun; 2019 Dec; 10(1):5817. PubMed ID: 31862961
[TBL] [Abstract][Full Text] [Related]
10. The MD Anderson Prostate Cancer Patient-derived Xenograft Series (MDA PCa PDX) Captures the Molecular Landscape of Prostate Cancer and Facilitates Marker-driven Therapy Development.
Palanisamy N; Yang J; Shepherd PDA; Li-Ning-Tapia EM; Labanca E; Manyam GC; Ravoori MK; Kundra V; Araujo JC; Efstathiou E; Pisters LL; Wan X; Wang X; Vazquez ES; Aparicio AM; Carskadon SL; Tomlins SA; Kunju LP; Chinnaiyan AM; Broom BM; Logothetis CJ; Troncoso P; Navone NM
Clin Cancer Res; 2020 Sep; 26(18):4933-4946. PubMed ID: 32576626
[TBL] [Abstract][Full Text] [Related]
11. Target Discovery for Precision Medicine Using High-Throughput Genome Engineering.
Guo X; Chitale P; Sanjana NE
Adv Exp Med Biol; 2017; 1016():123-145. PubMed ID: 29130157
[TBL] [Abstract][Full Text] [Related]
12. CRISPR/Cas9: From Genome Engineering to Cancer Drug Discovery.
Luo J
Trends Cancer; 2016 Jun; 2(6):313-324. PubMed ID: 28603775
[TBL] [Abstract][Full Text] [Related]
13. Use of CRISPR/Cas9 gene-editing tools for developing models in drug discovery.
Ahmad G; Amiji M
Drug Discov Today; 2018 Mar; 23(3):519-533. PubMed ID: 29326075
[TBL] [Abstract][Full Text] [Related]
14. Genome-wide CRISPR screens for the identification of therapeutic targets for cancer treatment.
Xue VW; Wong SCC; Cho WCS
Expert Opin Ther Targets; 2020 Nov; 24(11):1147-1158. PubMed ID: 32893711
[TBL] [Abstract][Full Text] [Related]
15. CRISPR/Cas9 Editing to Facilitate and Expand Drug Discovery.
Robert F; Huang S; Pelletier J
Curr Gene Ther; 2017; 17(4):275-285. PubMed ID: 29173168
[TBL] [Abstract][Full Text] [Related]
16. Application of CRISPR/Cas9 to human-induced pluripotent stem cells: from gene editing to drug discovery.
De Masi C; Spitalieri P; Murdocca M; Novelli G; Sangiuolo F
Hum Genomics; 2020 Jun; 14(1):25. PubMed ID: 32591003
[TBL] [Abstract][Full Text] [Related]
17. Genome-wide CRISPR/Cas9 knockout screening uncovers a novel inflammatory pathway critical for resistance to arginine-deprivation therapy.
Chu CY; Lee YC; Hsieh CH; Yeh CT; Chao TY; Chen PH; Lin IH; Hsieh TH; Shih JW; Cheng CH; Chang CC; Lin PS; Huang YL; Chen TM; Yen Y; Ann DK; Kung HJ
Theranostics; 2021; 11(8):3624-3641. PubMed ID: 33664852
[TBL] [Abstract][Full Text] [Related]
18. CRISPR/Cas9: A powerful genome editing technique for the treatment of cancer cells with present challenges and future directions.
Hazafa A; Mumtaz M; Farooq MF; Bilal S; Chaudhry SN; Firdous M; Naeem H; Ullah MO; Yameen M; Mukhtiar MS; Zafar F
Life Sci; 2020 Dec; 263():118525. PubMed ID: 33031826
[TBL] [Abstract][Full Text] [Related]
19. Applications and advances of CRISPR-Cas9 in cancer immunotherapy.
Xia AL; He QF; Wang JC; Zhu J; Sha YQ; Sun B; Lu XJ
J Med Genet; 2019 Jan; 56(1):4-9. PubMed ID: 29970486
[TBL] [Abstract][Full Text] [Related]
20. Gene Therapy with CRISPR/Cas9 Coming to Age for HIV Cure.
Soriano V
AIDS Rev; 2017; 19(3):167-172. PubMed ID: 29019352
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
